Precision BioSciences, Inc. (DTIL)
- Previous Close
9.68 - Open
9.67 - Bid 10.08 x 100
- Ask 10.45 x 200
- Day's Range
9.52 - 10.36 - 52 Week Range
8.25 - 27.03 - Volume
31,095 - Avg. Volume
128,978 - Market Cap (intraday)
70.753M - Beta (5Y Monthly) 1.57
- PE Ratio (TTM)
-- - EPS (TTM)
-332.12 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.80
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
www.precisionbiosciences.comRecent News: DTIL
Performance Overview: DTIL
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DTIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DTIL
Valuation Measures
Market Cap
71.51M
Enterprise Value
-13.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.03
Price/Book (mrq)
3.79
Enterprise Value/Revenue
-0.29
Enterprise Value/EBITDA
0.43
Financial Highlights
Profitability and Income Statement
Profit Margin
-125.84%
Return on Assets (ttm)
-13.74%
Return on Equity (ttm)
-107.26%
Revenue (ttm)
48.73M
Net Income Avi to Common (ttm)
-42.53M
Diluted EPS (ttm)
-332.12
Balance Sheet and Cash Flow
Total Cash (mrq)
116.68M
Total Debt/Equity (mrq)
165.78%
Levered Free Cash Flow (ttm)
-50.41M